209 related articles for article (PubMed ID: 10325957)
1. Effects of long-term angiotensin II AT1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats.
Richer C; Fornes P; Cazaubon C; Domergue V; Nisato D; Giudicelli JF
Cardiovasc Res; 1999 Jan; 41(1):100-8. PubMed ID: 10325957
[TBL] [Abstract][Full Text] [Related]
2. Effects of angiotensin II AT1-receptor blockade on coronary dynamics, function, and structure in postischemic heart failure in rats.
Gervais M; Fornes P; Richer C; Nisato D; Giudicelli JF
J Cardiovasc Pharmacol; 2000 Sep; 36(3):329-37. PubMed ID: 10975590
[TBL] [Abstract][Full Text] [Related]
3. Additive amelioration of left ventricular remodeling and molecular alterations by combined aldosterone and angiotensin receptor blockade after myocardial infarction.
Fraccarollo D; Galuppo P; Schmidt I; Ertl G; Bauersachs J
Cardiovasc Res; 2005 Jul; 67(1):97-105. PubMed ID: 15949473
[TBL] [Abstract][Full Text] [Related]
4. Comparative effects of chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade on cardiac remodeling after myocardial infarction in the rat.
Schieffer B; Wirger A; Meybrunn M; Seitz S; Holtz J; Riede UN; Drexler H
Circulation; 1994 May; 89(5):2273-82. PubMed ID: 8181153
[TBL] [Abstract][Full Text] [Related]
5. Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle.
Ambrose J; Pribnow DG; Giraud GD; Perkins KD; Muldoon L; Greenberg BH
J Cardiovasc Pharmacol; 1999 Mar; 33(3):433-9. PubMed ID: 10069680
[TBL] [Abstract][Full Text] [Related]
6. Angiotensin II subtype-1 receptor blockade during the development of left ventricular hypertrophy in dogs: effects on ventricular and myocyte function.
Spinale FG; Holzgrefe HH; Walker JD; Mukherjee R; Kribbs SB; Powell JR; Antonaccio M
J Cardiovasc Pharmacol; 1997 Nov; 30(5):623-31. PubMed ID: 9388045
[TBL] [Abstract][Full Text] [Related]
7. Selective ETA receptor blockade prevents left ventricular remodeling and deterioration of cardiac function in experimental heart failure.
Mulder P; Richard V; Bouchart F; Derumeaux G; Münter K; Thuillez C
Cardiovasc Res; 1998 Sep; 39(3):600-8. PubMed ID: 9861302
[TBL] [Abstract][Full Text] [Related]
8. AT1 receptor blockade prevents cardiac dysfunction after myocardial infarction in rats.
Berthonneche C; Sulpice T; Tanguy S; O'Connor S; Herbert JM; Janiak P; de Leiris J; Boucher F
Cardiovasc Drugs Ther; 2005 Aug; 19(4):251-9. PubMed ID: 16193242
[TBL] [Abstract][Full Text] [Related]
9. Comment on "Effects of long-term angiotensin II AT-1 receptor blockade on survival, hemodynamics and cardiac remodeling in chronic heart failure in rats".
Willenheimer R
Cardiovasc Res; 1999 Aug; 43(2):500-1. PubMed ID: 10536680
[No Abstract] [Full Text] [Related]
10. Dose-related beneficial long-term hemodynamic and clinical efficacy of irbesartan in heart failure.
Havranek EP; Thomas I; Smith WB; Ponce GA; Bilsker M; Munger MA; Wolf RA
J Am Coll Cardiol; 1999 Apr; 33(5):1174-81. PubMed ID: 10193713
[TBL] [Abstract][Full Text] [Related]
11. Combined selective angiotensin II AT1-receptor blockade and angiotensin I-converting enzyme inhibition on coronary flow reserve in postischemic heart failure in rats.
Richer C; Gervais M; Fornes P; Giudicelli JF
J Cardiovasc Pharmacol; 1999 Dec; 34(6):772-81. PubMed ID: 10598119
[TBL] [Abstract][Full Text] [Related]
12. Comparison of irbesartan with captopril effects on cardiac hypertrophy and gene expression in heart failure-prone male SHHF/Mcc-fa(cp) rats.
Carraway JW; Park S; McCune SA; Holycross BJ; Radin MJ
J Cardiovasc Pharmacol; 1999 Mar; 33(3):451-60. PubMed ID: 10069682
[TBL] [Abstract][Full Text] [Related]
13. AT1 angiotensin II receptor inhibition in pacing-induced heart failure: effects on left ventricular performance and regional blood flow patterns.
Clair MJ; Krombach RS; Hendrick JW; Houck WV; Hebbar L; Kribbs SB; Rios G; Whitebread S; Mukherjee R; de Gasparo M; Spinale FG
J Card Fail; 1998 Dec; 4(4):311-23. PubMed ID: 9924853
[TBL] [Abstract][Full Text] [Related]
14. Effects of ACE inhibition and angiotensin II type 1 receptor blockade on cardiac function and G proteins in rats with chronic heart failure.
Yoshida H; Takahashi M; Tanonaka K; Maki T; Nasa Y; Takeo S
Br J Pharmacol; 2001 Sep; 134(1):150-60. PubMed ID: 11522607
[TBL] [Abstract][Full Text] [Related]
15. Effects of differential blockade of the renin-angiotensin system in postinfarcted rats.
Lacour C; Roccon A; Galindo G; Canals F; Hogie M; Segondy D; Briand D; Roque C; Herbert JM; Nisato D
Fundam Clin Pharmacol; 2004 Jun; 18(3):299-307. PubMed ID: 15147281
[TBL] [Abstract][Full Text] [Related]
16. Effect of crossing over hypertensive patients from a beta-blocker to an angiotensin receptor antagonist on resistance artery structure and on endothelial function.
Schiffrin EL; Park JB; Pu Q
J Hypertens; 2002 Jan; 20(1):71-8. PubMed ID: 11791028
[TBL] [Abstract][Full Text] [Related]
17. Combined effects of angiotensin converting enzyme inhibition and angiotensin II receptor antagonism in conscious pigs with congestive heart failure.
Shen YT; Wiedmann RT; Greenland BD; Lynch JJ; Grossman W
Cardiovasc Res; 1998 Aug; 39(2):413-22. PubMed ID: 9798526
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin AT1 receptor inhibition. Effects on hypertrophic remodeling and ACE expression in rats with pressure-overload hypertrophy due to ascending aortic stenosis.
Weinberg EO; Lee MA; Weigner M; Lindpaintner K; Bishop SP; Benedict CR; Ho KK; Douglas PS; Chafizadeh E; Lorell BH
Circulation; 1997 Mar; 95(6):1592-600. PubMed ID: 9118530
[TBL] [Abstract][Full Text] [Related]
19. Endothelial dysfunction in congestive heart failure: ACE inhibition vs. angiotensin II antagonism.
Schäfer A; Fraccarollo D; Tas P; Schmidt I; Ertl G; Bauersachs J
Eur J Heart Fail; 2004 Mar; 6(2):151-9. PubMed ID: 14984722
[TBL] [Abstract][Full Text] [Related]
20. Valsartan and coronary haemodynamics in early post-myocardial infarction in rats.
Gervais M; Richer C; Fornes P; De Gasparo M; Giudicelli JF
Fundam Clin Pharmacol; 1999; 13(6):635-45. PubMed ID: 10626750
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
